Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
OranjeBTC Buys Back 1,000,700 Shares for R$ 6.9 Million

OranjeBTC Buys Back 1,000,700 Shares for R$ 6.9 Million

BitgetBitget2026/11/09 01:01
  • OranjeBTC repurchased 1,000,700 common shares for BRL 6.9 million during November 3-8, 2026.
  • The average repurchase price was BRL 6.8981, with the shares’ discount to mNAV narrowing slightly by week-end.
  • Bitcoin per share rose 0.73% during the week to 2,874 satoshis.
  • Week-end Bitcoin reserves totaled 3,950 BTC, with 137,452,180 common shares outstanding, excluding treasury shares.
  • Gross Bitcoin yield reached 2.8% for the fourth quarter of 2026, versus 25.44% year to date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oranjebtc SA Educacao e Investimento published the original content used to generate this news brief on November 08, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss